Expression Levels of Seprase/FAPα and DPPIV/CD26 in Epithelial Ovarian Carcinoma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2015 Jul 15

PMID 26170973

Citations 25

Authors

Mengzhen Zhang

Liwei Xu

Xiaoling Wang

Beibei Sun

Juan Ding

Affiliations

Soon will be listed here.

Abstract

Dipeptidyl peptidase IV (DPPIV; also known as cluster of differentiation 26) and the surface-expressed protease, seprase [also known as fibroblast activation protein alpha (FAPα)], are able to degrade the extracellular matrix; therefore, they are involved in malignant cell invasion and metastasis. However, the prognostic implications of their overexpression in carcinomas remain controversial. The aim of the present study was to investigate the expression and potential prognostic effects of DPPIV and seprase in cases of ovarian carcinoma. Immunohistochemical analysis (IHC) was performed to assess the protein expression of DPPIV and seprase/FAPα in 199 patients (malignant epithelial ovarian cancer, 128; borderline ovarian tumors, 41; and benign ovarian tumors, 30). In addition, hybridization was used to detect the mRNA expression levels of DPPIV and seprase in 86 malignant epithelial ovarian cancer samples. IHC revealed positive staining for seprase and DPPIV proteins in 110/128 (85.94%) and 106/128 (82.81%) patients with ovarian cancer, respectively. Seprase and DPPIV protein expression was associated with lymph node metastasis and the International Federation of Gynecology and Obstetrics stage. By contrast, no significant correlation was detected between the proteins and the patient age or histological grade and type of tumor. Immunostaining was stronger in the cancerous tissues compared with the borderline and benign tissues. Increased levels of seprase, but not DPPIV, were significantly associated with a shorter disease-free survival (P=0.033). Further analysis revealed that 96.5 (83/86) and 97.67% (84/86) of the malignant epithelial ovarian cancer samples stained positively for seprase and DPPIV mRNA, respectively. Therefore, DPPIV and seprase may be involved in the development of ovarian cancer, and that they are potential predictive markers of epithelial ovarian carcinoma.

Citing Articles

Head-to-head comparison of F-FDG and Ga-FAPI PET/CT in common gynecological malignancies.

Li T, Zhang J, Yan Y, Zhang Y, Pei W, Hua Q Cancer Imaging. 2025; 25(1):21.

PMID: 40022239 PMC: 11869701. DOI: 10.1186/s40644-025-00843-7.

DPP4, a potential tumor biomarker, and tumor therapeutic target: review.

Sun L, Ma Y, Geng C, Gao X, Li X, Ru Q Mol Biol Rep. 2025; 52(1):126.

PMID: 39821530 DOI: 10.1007/s11033-025-10235-6.

Association of serum and salivary dipeptidyl peptidase-4 (DPP-4) with oral cancerous and precancerous lesions; an observational diagnostic accuracy study.

Abdel Fattah Tarrad N, Shaker O, Abdelkawy M, Hassan S BMC Oral Health. 2024; 24(1):1206.

PMID: 39390508 PMC: 11468375. DOI: 10.1186/s12903-024-04939-7.

Fibroblast Activation Protein-α and the Immune Landscape: Unraveling T1 Non-muscle-invasive Bladder Cancer Progression.

Muilwijk T, Baekelandt L, Akand M, Daelemans S, Marien K, Waumans Y Eur Urol Open Sci. 2024; 66:67-74.

PMID: 39044944 PMC: 11263494. DOI: 10.1016/j.euros.2024.06.011.

Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial.

Bentestuen M, Ladekarl M, Knudsen A, Zacho H BMC Cancer. 2024; 24(1):699.

PMID: 38849741 PMC: 11157941. DOI: 10.1186/s12885-024-12461-w.

References

Okada K, Chen W, Iwasa S, Jin X, Yamane T, Ooi A . Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer. Oncology. 2004; 65(4):363-70. DOI: 10.1159/000074650. View

Wilson M, Ruhland A, Quast B, Reddy P, Ewing S, Sinha A . Dipeptidylpeptidase IV activities are elevated in prostate cancers and adjacent benign hyperplastic glands. J Androl. 2000; 21(2):220-6. View

OBrien P, OConnor B . Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta. 2008; 1784(9):1130-45. DOI: 10.1016/j.bbapap.2008.01.006. View

Wikberg M, Edin S, Lundberg I, van Guelpen B, Dahlin A, Rutegard J . High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol. 2013; 34(2):1013-20. PMC: 3597266. DOI: 10.1007/s13277-012-0638-2. View

Chen W, Kelly T, Ghersi G . DPPIV, seprase, and related serine peptidases in multiple cellular functions. Curr Top Dev Biol. 2003; 54:207-32. DOI: 10.1016/s0070-2153(03)54010-8. View

Bakrin N, Bereder J, Decullier E, Classe J, Msika S, Lorimier G . Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013; 39(12):1435-43. DOI: 10.1016/j.ejso.2013.09.030. View

Talvensaari-Mattila A, Santala M, Soini Y, Turpeenniemi-Hujanen T . Prognostic value of matrix metalloproteinase-2 (MMP-2) expression in endometrial endometrioid adenocarcinoma. Anticancer Res. 2005; 25(6B):4101-5. View

Lai D, Ma L, Wang F . Fibroblast activation protein regulates tumor-associated fibroblasts and epithelial ovarian cancer cells. Int J Oncol. 2012; 41(2):541-50. DOI: 10.3892/ijo.2012.1475. View

Jin X, Iwasa S, Okada K, Mitsumata M, Ooi A . Expression patterns of seprase, a membrane serine protease, in cervical carcinoma and cervical intraepithelial neoplasm. Anticancer Res. 2003; 23(4):3195-8. View

10.

Khin E, Kikkawa F, Ino K, Kajiyama H, Suzuki T, Shibata K . Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade. Am J Obstet Gynecol. 2003; 188(3):670-6. DOI: 10.1067/mob.2003.169. View

11.

Kennedy A, Dong H, Chen D, Chen W . Elevation of seprase expression and promotion of an invasive phenotype by collagenous matrices in ovarian tumor cells. Int J Cancer. 2008; 124(1):27-35. PMC: 2597700. DOI: 10.1002/ijc.23871. View

12.

Miyake Y, Aratake Y, Sakaguchi T, Kiyoya K, Kuribayashi T, Marutsuka K . Examination of CD26/DPPIV, p53, and PTEN expression in thyroid follicular adenoma. Diagn Cytopathol. 2011; 40(12):1047-53. DOI: 10.1002/dc.21725. View

13.

Kajiyama H, Kikkawa F, Suzuki T, Shibata K, Ino K, Mizutani S . Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma. Cancer Res. 2002; 62(10):2753-7. View

14.

Goscinski M, Suo Z, Nesland J, Florenes V, Giercksky K . Dipeptidyl peptidase IV expression in cancer and stromal cells of human esophageal squamous cell carcinomas, adenocarcinomas and squamous cell carcinoma cell lines. APMIS. 2008; 116(9):823-31. DOI: 10.1111/j.1600-0463.2008.01029.x. View

15.

Pro B, Dang N . CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopathol. 2004; 19(4):1345-51. DOI: 10.14670/HH-19.1345. View

16.

Benedet J, Bender H, Jones 3rd H, Ngan H, Pecorelli S . FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000; 70(2):209-62. View

17.

Kelly T, Kechelava S, Rozypal T, West K, Korourian S . Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancers. Mod Pathol. 1998; 11(9):855-63. View

18.

Monsky W, Lin C, Aoyama A, Kelly T, Akiyama S, Mueller S . A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res. 1994; 54(21):5702-10. View

19.

Deakin N, Chaplain M . Mathematical modeling of cancer invasion: the role of membrane-bound matrix metalloproteinases. Front Oncol. 2013; 3:70. PMC: 3615222. DOI: 10.3389/fonc.2013.00070. View

20.

Kotackova L, Balaziova E, Sedo A . Expression pattern of dipeptidyl peptidase IV activity and/or structure homologues in cancer. Folia Biol (Praha). 2009; 55(3):77-84. View